The Society of Gynecologic Oncology of Canada

To improve the care of women with or at risk of gynecologic cancer by raising standards of practice, encouraging ongoing research, promoting innovation in prevention, care and discovery, and advancing awareness. GOC also seeks to disseminate knowledge to practitioners, patients and the general public on gynecologic cancer as well as cooperate with other organizations committed to women’s health care, oncology, and related fields.​​

https://www.gyneoncology.ca

Contact us

Powered By

This is a past event. Registration is closed. View other The Society of Gynecologic Oncology of Canada events.

Event Details

Registration for the 22nd Continuing Professional Development Meeting is now closed!


Are you registered for the meeting? Go to the email from SpotMe (noreply@spotme.com) that was previously sent to you to give you access to the event. Please access the event platform to get the zoom link and to see the agenda in your own time zone. Once on the platform, click on today's date and on the first session to get the zoom link which is at the bottom of the page. Note that your web access link is unique and cannot be shared.

Questions? Send us an email at enquiry@gyneoncology.ca.



It is with great pleasure that we invite you on behalf of the Executive of The Society of Gynecologic Oncology of Canada and the CPD Program Planning Committee to attend the 22nd Annual Continuing Professional Development meeting. We have an outstanding array of local, national, and international speakers who will be presenting a variety of exciting topics with this year's theme as: Expanding Treatment Paradigms in Gynecologic Oncology.


At the end of this program, participants will be able to:

  • Discuss the management of obese patients.
  • Identify sarcopenic obesity as a precursor to gynecologic cancer and review the role of nutrition in mitigating it.
  • Integrate frailty into the treatment plan of patients.
  • Review the latest findings on PARP Inhibitors in ovarian cancer.
  • Examine the role of immune therapy in the management of endometrial cancer.
  • Analyze the management of immune-related toxicities.


This is a virtual meeting. Please note that all times in the agenda below are in PST. You can download the agenda in various time zones below.

Agenda

April 28, 2022

Main Schedule

07:50 - 08:00
Welcome & Introduction
Patti Power (Divisional Head Gynecologic Oncology at H Bliss Cancer Center)
Patti Power
Dr. Power is the Divisional Chief of Gynecologic Oncology within Eastern Health and is a MUN Associate Professor within the Women’s Health program. She is a graduate of Memorial’s Medical School and completed her fellowship in Gynecologic Oncology in Calgary as well as a Diploma in Clinical Epidemiology at Memorial. She has been an active mentor in the Obstetrics and Gynecology program at MUN for many years, is an active member of the Residency Training Program for Obstetrics and Gynecology and is the Competency by Design Lead for that program. She has been a Royal College examiner for Obstetrics and Gynecology for the past 5 years and has now joined the Gynecologic Oncology Royal College Nucleus Committee. She is past president of The Society of Canadian Colposcopists and previous chair of the Subspecialties Committee of Academic Professionals in Obstetrics and Gynecology (APOG) of Canada. She is also an active member of the Scientific Advisory Committee for the H. Bliss Murphy Cancer Center. She has a special interest in student well-being and looks forward to positively contributing to the success of Memorial’s undergraduate and postgraduate medical students.
08:00 - 08:40
A Multidisciplinary Approach to the Management of Obesity in the Gynecologic Oncology Patient
At the end of this session, participants will learn to:
1. Review the intersection between obesity and gyne oncology​
2. Weight bias in medicine (and how we need to do better)​
3. Explore compassionate ways to address obesity with your patients​
4. Understand effective multidisciplinary treatment for obesity​
Sasha High, FRCPC, ABOM (Founder and CEO of High Metabolic Clinic)
Sasha High, FRCPC, ABOM
Dr. Sasha High is an Internist and Obesity Medicine Physician, mom of 3, kitesurfer, entrepreneur and CEO. She completed a Bachelor of Science at the University of Ottawa, then medical school and residency at the University of Toronto. Dr. High is board-certified in Obesity Medicine and is a certified Life Coach. She has also received additional training in nutrition, CBT and ACT. Dr. High is the Founder of the High Metabolic Clinic, a multidisciplinary weight management clinic for women in Ontario, Nova Scotia and Newfoundland. The HMC team consists of Endocrinologists, Internists, Psychiatrists, Psychotherapists, Registered Dietitians and Certified Life Coaches. Their evidence-based approach involves behaviour change counselling, dietary guidance, mindset coaching and medical treatment to help women lose weight sustainably, stop emotional eating, and learn to love and accept themselves and their bodies. Dr. High is an international speaker and educator; and leverages her social media presence to educate and inspire women. She is also the host of the High on Life podcast, which empowers women with the medicine and the mindset to lose weight for good and thrive beyond the scale.
08:40 - 09:20
Sarcopenic Obesity: A New Face of an Old Problem in Gynecological Cancer and How Nutrition Can Help
At the end of this session, participants will be: 1. Describe hidden abnormalities in body composition. 2. Recognize the prevalence and significance of sarcopenic obesity in gynecological cancer. 3. Explain how targeted nutrition intervention can prevent/treat sarcopenic obesity.
Carla Prado (Professor, Department of Agricultural, Food and Nutritional Science at University of Alberta)
Carla Prado
Dr. Carla Prado is a Professor at the University of Alberta in Canada and a Campus Alberta Innovate Program (CAIP) chair in Nutrition, Food and Health. She is also the director of the Human Nutrition Research Unit. She is an expert in assessing nutritional status through the precise measurement of body composition and energy metabolism. The focus of her current research program is to develop targeted nutrition interventions for the prevention and treatment of low muscle mass in patients with diverse conditions. She is currently the principal investigator for four randomized controlled trials investigating the impact of nutrition intervention on body composition and health. She is an Editorial Board member of Clinical Nutrition, the Journal of Cachexia, Sarcopenia and Muscle, and Current Opinion in Clinical Nutrition and Metabolic Care. Dr. Prado is a past recipient of Canada’s Top 40 Under 40, an award that celebrates exceptional young Canadian leaders of all sectors, and she was recently inducted into the Royal Society of Canada, the highest academic honor in her country.
09:20 - 10:00
Incorporating Frailty Into the Treatment Plan of the Gynecologic Oncology Patient
At the end of this session, participants will be able to:​
1. Define frailty​
2. Describe the scope of the problem​
3. Explain how to recognize frailty in clinical practice​
4. Understand how frailty should impact treatment planning in the Gyn Onc patient
Erin Dean (MD at CancerCare Manitoba)
Erin Dean
10:00 - 10:30
First Break
10:30 - 11:10
PARP Inhibitors in Ovarian Cancer – Beyond the Basis
At the end of this session, participants will:​ 1. Recognize indication of PARP inhibitor in practice 2. understand Biomarkers of response and resistance​ 3. Discuss what’s next: potential new indication, new PARPi, new target​
Stephanie Lheureux, MD, PhD (Clinician Investigator at Princess Margaret Cancer Centre)
Stephanie Lheureux, MD, PhD
Dr. Lheureux obtained her MD in Medical Oncology and PhD in translational research from France and moved to Toronto for a Clinical Research Fellowship to focus on Gynecological Cancers and Drug Development. She is Site Lead, Gynecologic Oncology and Clinician Investigator at Princess Margaret Cancer Centre (PM) and holds an Assistant Professor position in the Faculty of Medicine, at the University of Toronto. She serves as co-Chair of the NCI Cervical Task Force on Clinical Trials and have served as a member of the Steering Committee on Uterine Cancers. She is Principal Investigator of several international studies and involved in the development of early phase clinical trials with an emphasis on drug development and translational research in gynecologic malignancies. Her academic interest is the design and development of early phase clinical trials of targeted agents in gynecologic cancers that incorporate translational endpoints and quality of life measures. This includes but is not limited to examination of chemoprevention approaches, targeted or precision therapies, immune-oncology agents, as well as leading improvements in quality of advanced cancer care. Academically, these interests have included interrogating extreme outliers of response and resistance across the disease continuum as a means of identifying predictors of therapeutic response. In particular, deep analysis of BRCA1/2 mutations in gynecologic cancers of high grade serous histology. In the last five years, she has >40 peer-reviewed publications in widely cited journals such as CA: Cancer Journal for Clinicians (IF=244), Clinical Cancer Research, JAMA Oncology, Journal of Clinical Oncology, Lancet Oncology and Gynecology Oncology. She is PI or co-PI in several large-scale peer reviewed funding opportunities from the Canadian Cancer Society Research Institute, Ontario Institute for Cancer Research and Terry Fox Research Institute that converge preclinical and clinical areas of interest and benefit from her unique expertise in each of these domains.
11:10 - 11:50
ICYMI ‘in case you missed it’ Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial- Gershenson et al.
At the end of this session, participants will​:
Understand the role of the MAPK pathway in low grade serous ovarian cancer​, Describe the role of MEK inhibition in the treatment of women with LGSC​ and Explain the benefits of trametinib compared to standard treatment in ou
Tamara Kuzma (Gynecologic Oncology Fellow at Tom Baker Cancer Centre, University of Calgary)
Tamara Kuzma
Dr. Kuzma is a second year Gynecologic Oncology fellow at the Tom Baker Cancer Centre at the University of Calgary. She completed medical school at the University of Alberta and residency in Obstetrics & Gynecology at the University of Saskatchewan. She earned her MSc in Public Health, with a specialization in Global Health from the University of Alberta. Her research and clinical interests include gynecologic oncology and access to surgical services in low income countries.
11:50 - 12:30
ICYMI ‘In Case You Missed It’ Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2-Swisher et al.
At the end of this session, participants will be:​ Familiar with the use of PARP in treatment of relapsed HGOC​, Familiar with genetic and epigenetic molecular profiling predicting response in HGOC ​ and Describe cross-resistance mechanisms to platinum and PAPRi​
Vishaal Gupta, MD, FRCSC (Gynaecologic Oncology Clinical Fellow at McGill University)
Vishaal Gupta, MD, FRCSC
Dr. Vishaal Gupta is currently in his 2nd year of fellowship in Gynecologic Oncology at McGill University in Montreal. He is originally from Toronto where he completed his residency at the University of Toronto. In addition to his daily work as a Gynecologic Oncology Fellow, he is completing his Masters in Public Health with a focus on Clinical Epidemiology and Biostatistics at Harvard University. Dr. Gupta, who will graduate in June 2022, is passionate about medicine and sharing his experiences with others.
12:30 - 13:00
Second Break
13:00 - 13:40
Management of Recurrent Uterine Leiomyosarcoma
At the end of this session, participants will be:​ Updated on the current standard of care for managing recurrent uterine leiomyosarcoma​. Informed on active areas of research in advanced uterine leiomyosarcoma
Jonathan Noujaim (Hematologist and Medical Oncologist Consultant at Hôpital Maisonneuve-Rosemont)
Jonathan Noujaim
Dr. Noujaim completed his internal medicine and hematology-oncology residency at Université de Montréal. He went on to complete a clinical research fellowship in sarcoma at the Royal Marsden Hospital and University College London Hospital. He is currently a medical oncology consultant at Hôpital Maisonneuve-Rosemont where he leads the sarcoma research program with a focus on cellular therapy trials.
13:40 - 14:20
Role of Immune Therapy in Management of Endometrial Cancer
At the end of this presentation, participants will be:​ Familiar with the efficacy of checkpoint inhibitors and checkpoint inhibitors in combination with VEGF-TKIs in Endometrial Cancer. Understand common adverse events of these therapeutics​. Become more familiar with adverse event management
Vicky Makker (Medical Oncologist at Memorial Sloan Kettering Cancer Center)
Vicky Makker
I am a medical oncologist who focuses on the medical treatment of gynecologic cancers. I also have a research interest in developing improved therapies for endometrial cancer.
14:20 - 15:00
A Primer for Managing Immune-Related Toxicities in the Gynecologic Oncology Patient
At the end of this session, participants will be:
Familiar with the unique toxicity profile of immune checkpoint inhibitors, Discuss the treatment of patients with immune-related events and Recognize and treat immune-related toxicity at its early stages.
Teresa Petrella (Medical Oncologist at Sunnybrook Health Sciences Centre)
Teresa Petrella
Teresa Petrella is a Medical Oncologist at the Sunnybrook Odette Cancer Centre in Toronto, Canada and an Associate Professor at the University of Toronto. Dr. Petrella has a BSc in Molecular Biology from the University of Western Ontario and completed her MD from Queen’s University. Her Internal Medicine and Medical Oncology training was at McMaster University. She subsequently completed a fellowship in Melanoma and Breast cancer at the Sunnybrook Odette Cancer Centre along with a Masters in Health Research Methodology at McMaster University. Dr. Petrella joined the staff at OCC in 2002 and became the Head of the Melanoma Site Group. She also Chairs the Provincial Guidelines Melanoma Disease Site Group, Program in Evidence Based Care. She is the past Chair of the Melanoma Canadian Cancer Trials Group (CCTG) and is currently the Medical Director of Clinical Trials at the Sunnybrook Odette Cancer Centre. A key focus of Dr. Petrella’s research is investigating novel immunotherapies and targeted therapies for the treatment of metastatic melanoma. She has been actively involved in the design and implementation of clinical trials for melanoma and non-melanoma skin cancers.
15:00 - 15:45
Case Presentation & Panel Discussion
At the end of this presentation, participants will be:​
1. Familiar with the efficacy of checkpoint inhibitors and checkpoint inhibitors in combination with VEGF-TKIs in Endometrial Cancer​
2. Understand common adverse events of these therapeutics​
3. Become more familiar with adverse event management ​
Marie-Helene Auclair (Gyne oncologist at Hôpital Maisonneuve-Rosemont)
Marie-Helene Auclair
Marie-Hélène Auclair is a gynecologic oncologist at Hôpital Maisonneuve-Rosemont, an academic hospital affiliated to the Université de Montréal. She did her medical school and OBGYN residency at McGill University and her gynecologic oncology fellowship at the CHUM/Université de Montréal. She started her practice in 2019. She became a diplomate of the American Board of Obesity Medicine in 2021 and is currently a candidate to the Queen’s University Master of Science in Healthcare Quality. Her special interests include endometrial pathologies, enhanced recovery pathways and survivorship.
Vicky Makker (Medical Oncologist at Memorial Sloan Kettering Cancer Center)
Vicky Makker
I am a medical oncologist who focuses on the medical treatment of gynecologic cancers. I also have a research interest in developing improved therapies for endometrial cancer.
Teresa Petrella (Medical Oncologist at Sunnybrook Health Sciences Centre)
Teresa Petrella
Teresa Petrella is a Medical Oncologist at the Sunnybrook Odette Cancer Centre in Toronto, Canada and an Associate Professor at the University of Toronto. Dr. Petrella has a BSc in Molecular Biology from the University of Western Ontario and completed her MD from Queen’s University. Her Internal Medicine and Medical Oncology training was at McMaster University. She subsequently completed a fellowship in Melanoma and Breast cancer at the Sunnybrook Odette Cancer Centre along with a Masters in Health Research Methodology at McMaster University. Dr. Petrella joined the staff at OCC in 2002 and became the Head of the Melanoma Site Group. She also Chairs the Provincial Guidelines Melanoma Disease Site Group, Program in Evidence Based Care. She is the past Chair of the Melanoma Canadian Cancer Trials Group (CCTG) and is currently the Medical Director of Clinical Trials at the Sunnybrook Odette Cancer Centre. A key focus of Dr. Petrella’s research is investigating novel immunotherapies and targeted therapies for the treatment of metastatic melanoma. She has been actively involved in the design and implementation of clinical trials for melanoma and non-melanoma skin cancers.
15:45 - 15:50
Closing Remarks
Patti Power (Divisional Head Gynecologic Oncology at H Bliss Cancer Center)
Patti Power
Dr. Power is the Divisional Chief of Gynecologic Oncology within Eastern Health and is a MUN Associate Professor within the Women’s Health program. She is a graduate of Memorial’s Medical School and completed her fellowship in Gynecologic Oncology in Calgary as well as a Diploma in Clinical Epidemiology at Memorial. She has been an active mentor in the Obstetrics and Gynecology program at MUN for many years, is an active member of the Residency Training Program for Obstetrics and Gynecology and is the Competency by Design Lead for that program. She has been a Royal College examiner for Obstetrics and Gynecology for the past 5 years and has now joined the Gynecologic Oncology Royal College Nucleus Committee. She is past president of The Society of Canadian Colposcopists and previous chair of the Subspecialties Committee of Academic Professionals in Obstetrics and Gynecology (APOG) of Canada. She is also an active member of the Scientific Advisory Committee for the H. Bliss Murphy Cancer Center. She has a special interest in student well-being and looks forward to positively contributing to the success of Memorial’s undergraduate and postgraduate medical students.

PDF Agenda

Speakers and Moderators

Marie-Helene Auclair (Gyne oncologist at Hôpital Maisonneuve-Rosemont)

Marie-Helene Auclair

Gyne oncologist at Hôpital Maisonneuve-Rosemont

Melica Brodeur (Research fellow at Memorial Sloan Kettering Cancer Center)

Melica Brodeur

Research fellow at Memorial Sloan Kettering Cancer Center

Erin Dean (MD at CancerCare Manitoba)

Erin Dean

MD at CancerCare Manitoba

Rachelle Findley (Gynecologic Oncologist at Nova Scotia Cancer Centre)

Rachelle Findley

Gynecologic Oncologist at Nova Scotia Cancer Centre

Vishaal Gupta, MD, FRCSC (Gynaecologic Oncology Clinical Fellow at McGill University)

Vishaal Gupta, MD, FRCSC

Gynaecologic Oncology Clinical Fellow at McGill University

Sasha High, FRCPC, ABOM (Founder and CEO of High Metabolic Clinic)

Sasha High, FRCPC, ABOM

Founder and CEO of High Metabolic Clinic

Tamara Kuzma (Gynecologic Oncology Fellow at Tom Baker Cancer Centre, University of Calgary)

Tamara Kuzma

Gynecologic Oncology Fellow at Tom Baker Cancer Centre, University of Calgary

Stephanie Lheureux, MD, PhD (Clinician Investigator at Princess Margaret Cancer Centre)

Stephanie Lheureux, MD, PhD

Clinician Investigator at Princess Margaret Cancer Centre

Vicky Makker (Medical Oncologist at Memorial Sloan Kettering Cancer Center)

Vicky Makker

Medical Oncologist at Memorial Sloan Kettering Cancer Center

Jonathan Noujaim (Hematologist and Medical Oncologist Consultant at Hôpital Maisonneuve-Rosemont)

Jonathan Noujaim

Hematologist and Medical Oncologist Consultant at Hôpital Maisonneuve-Rosemont

Teresa Petrella (Medical Oncologist at Sunnybrook Health Sciences Centre)

Teresa Petrella

Medical Oncologist at Sunnybrook Health Sciences Centre

Patti Power (Divisional Head Gynecologic Oncology at H Bliss Cancer Center)

Patti Power

Divisional Head Gynecologic Oncology at H Bliss Cancer Center

Carla Prado (Professor, Department of Agricultural, Food and Nutritional Science at University of Alberta)

Carla Prado

Professor, Department of Agricultural, Food and Nutritional Science at University of Alberta

Omar Touhami (CIUSSS du saguenay Lac-Saint-Jean)

Omar Touhami

CIUSSS du saguenay Lac-Saint-Jean

Sponsors and Partners

Planning Committee

The following provides you with the list of all the members of the CPD Program Planning Committee with their conflict of interest. 

PATTI POWER

CHAIR


Dr. Power is the Divisional Chief of Gynecologic Oncology within Eastern Health and is a MUN Associate Professor within the Women's Health program. She is a graduate of Memorial's Medical School and completed her fellowship in Gynecologic Oncology in Calgary as well as a Diploma in Clinical Epidemiology at Memorial. She has been an active mentor in the Obstetrics and Gynecology program at MUN for many years, is an active member of the Residency Training Program for Obstetrics and Gynecology and is the Competency by Design Lead for that program. She has been a Royal College examiner for Obstetrics and Gynecology for the past 5 years and has now joined the Gynecologic Oncology Royal College Nucleus Committee. She is past president of The Society of Canadian Colposcopists and previous chair of the Subspecialties Committee of Academic Professionals in Obstetrics and Gynecology (APOG) of Canada. She is also an active member of the Scientific Advisory Committee for the H. Bliss Murphy Cancer Center. She has a special interest in student well-being and looks forward to positively contributing to the success of Memorial's undergraduate and postgraduate medical students. 


Conflict of Interest Form (coming soon!)

HELEN MACKAY

EXECUTIVE REPRESENTATIVE / PRESIDENT


Dr. Helen MacKay is a Medical Oncologist and Professor of Medicine at the University of Toronto. She is Head of the Division of Medical Oncology and Hematology at the Odette Cancer Centre at Sunnybrook Health Sciences Centre, and Senior Scientist at the Sunnybrook Research Institute. Dr. MacKay's clinical practice and research focus is on gynecological cancers. Her research involves collaborating with translational and basic scientists in the development and validation of novel therapeutic strategies. She is the current President of the Society of Gynecologic Oncologists of Canada (GOC). She co-chairs the NCI (US), Ovarian Cancer Task Force. She also chairs the Ovarian Group and sits on the executive of the Gyne committee of the Canadian Cancer Trials Group (CCTG), and represents CCTG at the Gynecologic Cancer Intergroup. She is a past chair of both the Gynecologic Cancer Education and Scientific Committees for ASCO. With specific reference to uterine cancers, she is a member of the TRANSPORTEC group, and sits on the Corpus Committee of NRG, and was the co-chair of the NCI Endometrial Cancer Clinical Trials Planning Committee. 


Conflict of Interest Form (coming soon!)

ALON ALTMAN

EXECUTIVE REPRESENTATIVE / PRESIDENT-ELECT


Dr. Alon Altman is a professor of obstetrics, gynecology and reproductive sciences at the Rady Faculty of Health Sceinces. He is also a gynecologic oncologist at the Health Sciences Centre/Cancercare Manitoba.

He has a strong interest in undergraduate/postgraduate education and research.

Dr. Altman is the president elect for the Society of Gynecologic Oncology of Canada (GOC), the program director for the department of Obstetrics and Gynecology, chair of the University Medical Group (UMG), vice chair for the Medical Management Safety Committee (MMSC) at CancerCare Manitoba, the current Gynecologic oncology track lead for the FIGO 2021 Scientific planning committee and the previous co-chair of the Canadian Obstetrics and Gynecology Review program (COGRP).

He is actively involved in multiple university, national and international committees.


Conflict of Interest Form (coming soon!)

JACOB MCGEE

EXECUTIVE REPRESENTATIVE / SECRETARY-TREASURER


Jacob McGee is a gynecologic oncologist and an associate professor in the Schulich School of Medicine at Western University. He is the regional gynecologic oncology champion for southwestern Ontario, a Director for the Gynecologic Oncology Group of Ontario (GOGO), and the incoming Secretary-Treasurer for The Society of Gynecologic Oncology of Canada. His research interests include optimizing testing for hereditary cancer syndromes and outcomes research using ICES (institute for clinical evaluative sciences) datasets.   


Conflict of Interest Form (coming soon!)

STEPHEN WELCH

MEMBER



Conflict of Interest Form (coming soon!)

MARIE-HELENE AUCLAIR

MEMBER




Conflict of Interest Form (coming soon!)

OMAR TOUHAMI

MEMBER




Conflict of Interest Form (coming soon!)

JOANNE POWER

MEMBER / NURSE REPRESENTATIVE




Conflict of Interest Form (coming soon!)

RACHELLE FINDLEY

MEMBER / COMMUNICATIONS REPRESENTATIVE


Rachelle Findley hails from rural Southern Alberta. She completed her Bachelor of Science in Pharmacy at the University of Alberta and worked as a community pharmacist throughout her Medical degree in Edmonton. Obstetrics and Gynecology residency took her across the country to Halifax at Dalhousie University.

 

Having recently completed Gynecologic Oncology fellowship through the University of Calgary in 2021, she has since worked with the Gynecologic Oncology team at the Allan Blair Cancer Centre in Regina and started a master's program with the Johnson Shoyama Graduate School of Public Policy.



Conflict of Interest Form (coming soon!)

MARK CAREY

MEMBER / CHAIR, BIOLOGY COURSE


He completed his medical degree and Obstetrics & Gynaecology residency at the University of Western Ontario, a fellowship in Gynaecologic Oncology at the University of Toronto and McMaster University, and a research fellowship in the Department of Systems Biology at the University of Texas, MD Anderson Cancer Centre. He runs his research program through OvCaRe and has funding through private donations and his medical corporation to support his laboratory staff. He is Co-Investigator on a recent grant award from the Cancer Research Society with Dr. Cheng-Han Lee, and has done contract research for investigational drug testing. His laboratory has been supported as well by research funds from Dr. Dianne Miller and the Division of Gyn Oncology, the BC Cancer Agency, the Carraresi Foundation OvCaRe Research Grant, and VGH and UBC Hospital Foundations. Mark regularly supervises PhD and MSc candidates and is a member of the department's Research Advisory Committee.



Conflict of Interest Form (coming soon!)

TOMER FEIGENBERG

MEMBER / CHAIR, AGM PLANNING COMMITTEE




Conflict of Interest Form (coming soon!)

MELICA BRODEUR

MEMBER



Conflict of Interest Form (coming soon!)

SARAH SINASAC

EXECUTIVE REPRESENTATIVE / DIRECTOR OF EDUCATION


Dr. Sinasac is a Gynecologic Oncologist at The Ottawa Hospital, and an Assistant Professor at the University of Ottawa. She completed residency in Obstetrics and Gynecology and fellowship in Gynecologic Oncology at the University of Toronto. During fellowship she completed her Master's degree in Public Health at Harvard University. She is the Gynecologic Oncology Fellowship Program Director at the University of Ottawa. She is the Chair of the Education Committee at the GOC, and the founder and co-Chair of the Community of Practice in Obesity. She has extensive training and experience in advanced laparoscopic surgery and has an interest in surgical skills education. 


Conflict of Interest Form (coming soon!)

LAURENCE BERNARD

MEMBER




Conflict of Interest Form (coming soon!)

SABRINA PIEDIMONTE

MEMBER / FELLOW REPRESENTATIVE




Conflict of Interest Form (coming soon!)

Recordings

Session I

A Multidisciplinary Approach to the Management of Obesity in the Gynecologic Oncology Patient - Dr. Sasha High


At the end of this session, participants will learn to:

  1. Review the intersection between obesity and gyne oncology​.
  2. Weight bias in medicine (and how we need to do better)​.
  3. Explore compassionate ways to address obesity with your patients​.
  4. Understand effective multidisciplinary treatment for obesity​.


Access the recording​.

Sarcopenic Obesity: A New Face of an Old Problem in Gynecological Cancer and How Nutrition Can Help - Dr. Carla Prado


At the end of this session, participants will be:

  1. Describe hidden abnormalities in body composition.
  2. Recognize the prevalence and significance of sarcopenic obesity in gynecological cancer.
  3. Explain how targeted nutrition intervention can prevent/treat sarcopenic obesity.


Access the recording​.

Incorporating Frailty Into the Treatment Plan of the Gynecologic Oncology Patient - Dr. Erin Dean


At the end of this session, participants will be able to:​

  1. Define frailty​.
  2. Describe the scope of the problem​
  3. Explain how to recognize frailty in clinical practice.
  4. Understand how frailty should impact treatment planning in the Gyn Onc patient.


Access the recording​.

Session II

PARP Inhibitors in Ovarian Cancer – Beyond the Basis - Dr. Stephanie Lheureux


At the end of this session, participants will:​

  1. Recognize indication of PARP inhibitor in practice.
  2. Understand Biomarkers of response and resistance.
  3. Discuss what's next: potential new indication, new PARPi, new target​.


Access the recording​.

ICYMI 'in case you missed it' Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial- Gershenson et al. - Dr. Tamara Kuzma


At the end of this session, participants will​:

  1. Understand the role of the MAPK pathway in low grade serous ovarian cancer​.
  2. Describe the role of MEK inhibition in the treatment of women with LGSC​.
  3. Explain the benefits of trametinib compared to standard treatment.


Access the recording​.

ICYMI 'In Case You Missed It' Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2-Swisher et al. - Dr. Vishaal Gupta


At the end of this session, participants will be:​

  1. Familiar with the use of PARP in treatment of relapsed HGOC​.
  2. Familiar with genetic and epigenetic molecular profiling predicting response in HGOC.
  3. Describe cross-resistance mechanisms to platinum and PARPi​.


Access the recording​.

Session III

Management of Recurrent Uterine Leiomyosarcoma - Dr. Jonathan Noujaim


At the end of this session, participants will be:​

  1. Updated on the current standard of care for managing recurrent uterine leiomyosarcoma​.
  2. Informed on active areas of research in advanced uterine leiomyosarcoma.


Access the recording​.

Role of Immune Therapy in Management of Endometrial Cancer - Dr. Vicky Makker


At the end of this presentation, participants will be:​

  1. Familiar with the efficacy of checkpoint inhibitors and checkpoint inhibitors in combination with VEGF-TKIs in Endometrial Cancer.
  2. Understand common adverse events of these therapeutics​. Become more familiar with adverse event management.


Access the recording​.

A Primer for Managing Immune-Related Toxicities in the Gynecologic Oncology Patient - Dr. Teresa Petrella


At the end of this session, participants will be:

  1. Familiar with the unique toxicity profile of immune checkpoint inhibitors.
  2. Discuss the treatment of patients with immune-related events.
  3. Recognize and treat immune-related toxicity at its early stages.


Access the recording​.

Case Presentation & Panel Discussion - Drs. Marie-Helene Auclair, Vicky Makker and Teresa Petrella


At the end of this presentation, participants will be:

  1. Familiar with the efficacy of checkpoint inhibitors and checkpoint inhibitors in combination with VEGF-TKIs in Endometrial Cancer​.
  2. Understand common adverse events of these therapeutics​.
  3. Become more familiar with adverse event management.


Access the recording​.